TY - JOUR
T1 - SOX2 expression associates with stem cell state in human ovarian carcinoma
AU - Bareiss, Petra M.
AU - Paczulla, Anna
AU - Wang, Hui
AU - Schairer, Rebekka
AU - Wiehr, Stefan
AU - Kohlhofer, Ursula
AU - Rothfuss, Oliver C.
AU - Fischer, Anna
AU - Perner, Sven
AU - Staebler, Annette
AU - Wallwiener, Diethelm
AU - Fend, Falko
AU - Fehm, Tanja
AU - Pichler, Bernd
AU - Kanz, Lothar
AU - Quintanilla-Martinez, Leticia
AU - Schulze-Osthoff, Klaus
AU - Essmann, Frank
AU - Lengerke, Claudia
N1 - Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 2013/9/1
Y1 - 2013/9/1
N2 - The SRY-related HMG-box family of transcription factors member SOX2 regulates stemness and pluripotency in embryonic stem cells and plays important roles during early embryogenesis. More recently, SOX2 expression was documented in several tumor types including ovarian carcinoma, suggesting an involvement of SOX2 in regulation of cancer stem cells (CSC). Intriguingly, however, studies exploring the predictive value of SOX2 protein expression with respect to histopathologic and clinical parameters report contradictory results in individual tumors, indicating that SOX2 may play tumor-specific roles. In this report, we analyze the functional relevance of SOX2 expression in human ovarian carcinoma. We report that in human serous ovarian carcinoma (SOC) cells, SOX2 expression increases the expression of CSC markers, the potential to form tumor spheres, and the in vivo tumor-initiating capacity, while leaving cellular proliferation unaltered. Moreover, SOX2-expressing cells display enhanced apoptosis resistance in response to conventional chemotherapies and TRAIL. Hence, our data show that SOX2 associates with stem cell state in ovarian carcinoma and induction of SOX2 imposes CSC properties on SOC cells. We propose the existence of SOX2-expressing ovarian CSCs as a mechanism of tumor aggressiveness and therapy resistance in human SOC.
AB - The SRY-related HMG-box family of transcription factors member SOX2 regulates stemness and pluripotency in embryonic stem cells and plays important roles during early embryogenesis. More recently, SOX2 expression was documented in several tumor types including ovarian carcinoma, suggesting an involvement of SOX2 in regulation of cancer stem cells (CSC). Intriguingly, however, studies exploring the predictive value of SOX2 protein expression with respect to histopathologic and clinical parameters report contradictory results in individual tumors, indicating that SOX2 may play tumor-specific roles. In this report, we analyze the functional relevance of SOX2 expression in human ovarian carcinoma. We report that in human serous ovarian carcinoma (SOC) cells, SOX2 expression increases the expression of CSC markers, the potential to form tumor spheres, and the in vivo tumor-initiating capacity, while leaving cellular proliferation unaltered. Moreover, SOX2-expressing cells display enhanced apoptosis resistance in response to conventional chemotherapies and TRAIL. Hence, our data show that SOX2 associates with stem cell state in ovarian carcinoma and induction of SOX2 imposes CSC properties on SOC cells. We propose the existence of SOX2-expressing ovarian CSCs as a mechanism of tumor aggressiveness and therapy resistance in human SOC.
UR - http://www.scopus.com/inward/record.url?scp=84883482019&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-12-4177
DO - 10.1158/0008-5472.CAN-12-4177
M3 - Journal articles
C2 - 23867475
AN - SCOPUS:84883482019
SN - 0008-5472
VL - 73
SP - 5544
EP - 5555
JO - Cancer Research
JF - Cancer Research
IS - 17
ER -